Molecularly guided therapy of neuroblastoma: A review of different approaches

Current Pharmaceutical Design

Volumn 12, Issue 18, 2006, Pages 2303-2317

  Tonini, Gian Paolo ^a   Pistoia, Vito ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

Angiogenesis; Apoptosis; Differentiation; Gene therapy; Immunotherapy; Minimal residual disease; MYCN; Neuroblastoma

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; ALITRETINOIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CYTOKINE; FENRETINIDE; GANGLIOSIDE GD2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; ISOTRETINOIN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PROTEIN MYCN; RETINOIC ACID; RETINOID; RETINOL DERIVATIVE; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VATALANIB;

ADRENERGIC SYSTEM; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DRUG HALF LIFE; DRUG MECHANISM; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE THERAPY; HUMAN; LETHALITY; METASTASIS; MINIMAL RESIDUAL DISEASE; MOLECULAR BIOLOGY; NEUROBLASTOMA; NEUROSURGERY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOLID TUMOR; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CHROMOSOME DELETION; CYTOKINES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASM, RESIDUAL; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; NUCLEAR PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; ONCOGENE PROTEINS; RETINOIDS;

EID: 33745146147     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777585193     Document Type: Review

References (145)

1. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. The International Neuroblastoma Pathology Classification (the Shimada System). Cancer, 1999; 86: 364-72.
2. Evans AE, Neuroblastoma: A historical perspective 1864-1998. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA Eds, Neuroblastoma. Amsterdam, Elsever; 2000; 1-6.
3. Olshan AF and Bunin GR. Epidemiology of Neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA Eds, Neuroblastoma. Amsterdam, Elsever; 2000; 33-7.
4. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. The Oncologist 2003; 8: 278-92.
5. Brodeur GM, Pritchard J, Berthold F, Carlsen NTL, Castel V, Castleberry RP, et al. Revision of the International criteria for neuroblastoma diagnosis, staging and response to treatment. J. Clin. Oncol. 1993; 11: 1466-77.
6. D'Angio GJ, Evans AE, Koop CE. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1971; 1: 1046-49.
7. Pritchard J, Hickman JA. Why does stage 4s neuroblastoma regress spontaneously? Lancet. 1994 Sep 24;344(8926):869-70
8. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature. 1983; 305: 245-48.
9. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985; 313: 1111-6.
10. Tonini GP, Boni L, Pession A, Rogers D, Iolascon A, Basso G, et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. J. Clin Oncol. 1997; 15: 85-93.
11. Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol. 2000;18:18-26.
12. Ambros IM, Benard J, Boavida M, Bown N, Caron H, Combaret V, et al. Quality assessment of genetic markers used for therapy stratification. J Clin Oncol. 2003; 21: 2077-84.
13. Gilbert F, Balaban G, Moorhead P, Bianchi D, Schlesinger H Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines. Cancer Genet Cytogenet. 1982; 7: 33-42.
14. Caron H, van Sluis P, de Kraker J, Bokkerink J, Egeler M, Laureys G. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med. 1996; 334:225-30.
15. Yuza Y, Agawa M, Matsuzaki M, Yamada H, Urashima M. Gene and protein expression profiling during differentiation of neuroblastoma cells triggered by 13-cis retinoic acid. J Pediatr Hematol Oncol 2003; 25: 715-20.
16. Iolascon A, Lo Cunsolo C, Giordani L, Cusano R, Boumgartner M, Ghisellini P, et al. Interstitial and large chromosome 1p deletion occurs in neuroblastoma of patients with both localized and disseminated tumours and predicts an unfavourable outcome. Cancer Letters 1998; 130: 83-92.
17. Krona C, Ejeskar K, Abel F, Kogner P, Bjelke J, Bjork E, et al. Screening for gene mutations in a 500 kb neuroblastoma tumor suppressor candidate region in chromosome 1p; mutation and stage-specific expression in UBE4B/UFD2. Oncogene. 2003; 22: 2343-51.
18. Maris JM, Guo C, Blake D, White PS, Hogarty MD, Thompson PM, et al. Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Med Pediatr Oncol. 2001; 36: 32-6.
19. White PS, Thompson PM, Seifried BA, Sulman EP, Jensen SJ, Guo C, et al. Detailed molecular analysis of 1p36 in neuroblastoma. Med Pediatr Oncol. 2001; 36: 37-41.
20. Maris JM, Kyemba SM, Rebbeck TR, White PS, Sulman EP, Jensen SJ. Familial predisposition to neuroblastoma does not map to chromosome band 1p36. Cancer Res. 1996; 56: 3421-15.
21. Tonini GP, McConville C, Cusano R, Rees SA, Dagnino M, Longo L, et al. Exclusion of Candidate Genes and Chromosomal Regions in Familial Neuroblastoma Int. J. Mol. Med. 2001; 7: 85-9.
22. Perri P, Longo L, Cusano R, McConville CM, Rees SA, Devoto M, et al. Weak linkage at 4p16 to predisposition for human neuroblastoma. Oncogene. 2002; 21: 8356-60.
23. Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999; 340: 1954-61.
24. Bown N. Neuroblastoma tumour genetics: clinical and biological aspects. J Clin Pathol. 2001; 54: 897-910.
25. Lo Cunsolo C, Bicocchi MP, Petti AR and Tonini GP. Numerical and structural aberrations in advanced neuroblastoma tumors by CGH analysis; survival correlates with chromosome 17 status. Br. J. Cancer 2000; 83: 1295-300.
26. Marshall B, Isidro G, Martins AG, Boavida MG Loss of heterozygosity at chromosome 9p21 in primary neuroblastomas: evidence for two deleted regions. Cancer Genet Cytogenet. 1997; 96: 134-39.
27. Iolascon A, Giordani L, Moretti A, Tonini GP, Lo Cunsolo C, Mastropietro S, et al. Structural and functional analysis of cyclindependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in neuroblastoma. Pediatr Res. 1998; 43: 139-44.
28. Giordani L, Iolascon A, Servedio V, Mazzocco K, Longo L, Tonini GP. Two regions of deletion in 9p22- p24 in neuroblastoma are frequently observed in favorable tumors. Cancer Genet Cytogenet. 2002;135: 42-7.
29. Mosse Y, Greshock J, King A, Khazi D, Weber BL, Maris JM. Identification and high-resolution mapping of a constitutional 11q deletion in an infant with multifocal neuroblastoma. Lancet Oncol. 2003; 4: 769-71.
30. Spitz R, Hero B, Ernestus K, Berthold F. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin Cancer Res. 2003; 9: 52-8.
31. Plantaz D, Vandesompele J, Van Roy N, Lastowska M, Bown N, Combaret V, et al. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer. 2001; 91: 680-86.
32. Thompson PM, Seifried BA, Kyemba SK, Jensen SJ, Guo C, Maris JM, et al. Loss of heterozygosity for chromosome 14q in neuroblastoma. Med Pediatr Oncol. 2001; 36: 28-31.
33. Hoshi M, Otagiri N, Shiwaku HO, Asakawa S, Shimizu N, Kaneko Y, et al. Detailed deletion mapping of chromosome band 14q32 in human neuroblastoma defines a 1.1-Mb region of common allelic loss. Br J Cancer. 2000; 82: 1801-07.
34. Brodeur GM, Nakagawara A, Yamashiro DJ, Ikegaki N, Liu XG, Azar CG, et al. Expression of TrkA, TrkB and TrkC in human neuroblastomas. J Neurooncol. 1997; 31: 49-55.
35. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003; 4: 472-80.
36. Tonini GP, Romani M. Genetic and epigenetic alterations in neuroblastoma. Cancer Lett. 2003; 197: 69-73.
37. Borrello MG, Bongarzone I, Pierotti MA, Luksch R, Gasparini M, Collini P, et al. TRK and RET proto-oncogene expression in human neuroblastoma speciments: high frequency of TRK expression in non-advanced stages. Int. J. Cancer 1993; 54: 540-45.
38. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; 3: 203-16.
39. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett. 2001; 169: 107-14.
40. van Noesel MM, Versteeg R. Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'. Gene. 2004; 325: 1-15
41. Maris JM, Matthay KK.Molecular biology of neuroblastoma. J Clin Oncol. 1999; 17: 2264-79.
42. Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem. 1987 262: 505-8.
43. Haber M, Bordow SB, Gilbert J, Madafiglio J, Kavallaris M, Marshall GM, et al. Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells. Oncogene. 1999 Apr 29;18(17):2777-82
44. Kurowski C, Berthold F. Presence of classical multidrug resistance and P-glycoprotein expression in human neuroblastoma cells. Ann Oncol 1998;9:1009-14.
45. Dhooge CR, De Moerloose BM, Benoit YC, Van Roy N, Philippe, Laureys GG. Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma. Cancer. 1997; 80: 1250-7.
46. Manohar CF, Bray JA, Salwen HR, Madafiglio J, Cheng A, Flemming C, et al. MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma. Oncogene 2004; 23: 753-62.
47. Goto H, Keshelava N, Matthay KK, Lukens JN, Gerbing RB, Stram DO, et al. Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors. Med Pediatr Oncol. 2000; 35: 619-22.
48. Ross AA. Minimal residual disease in solid tumor malignancies: a review. J Hematother. 1998; 7: 9-18
49. Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 1993; 6: 1134-7.
50. Handgretinger R, Leung W, Ihm K, Lang P, Klingebiel T, Niethammer D. Tumor cell contamination of autologous stem cells grafts in high-risk neuroblastoma: the good news? Br J Cancer 2003; 88: 1874-7.
51. Hafer R, Voigt A, Gruhn B, Zinti F. Neuroblastoma cells can express the hematopoietic progenitor cell antigen CD34 as detected at surface protein and mRNA level. J Neuroimmunol 1999; 96: 201-6.
52. Kanold J, Halle P, Tchirkov A, Berger M, Giarratana MC, Kobari L, et al. Ex vivo expansion of autologous PB CD34+ cells provides a purgino effect in children with neuroblastoma. Bone Marrow Transpl. 2003; 32: 485-8.
53. Riley RD, Heney D, Jones DR, Suton AJ, Lambert PC, Abrams KR, et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 2004; 10: 4-12.
54. Burchill SA, Lewis IJ, Abrams KR, Riley R, Imeson J Pearson AD, et al. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine-hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 2001; 19: 1795-801.
55. Faulkner LB, Garaventa A, Paoli A, Tintori V, Tamburini A, Lacitignola L, et al. In vivo cytoreduction studies and cell sorting-enhanced tumor-cell detection in high risk neuroblastoma patients: implications for leukapheresis strategies. J Clin Oncol 2000; 18: 3829-36.
56. Cheung IY, Lo Piccolo MS, Kushner BH, Cheung NK. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. J Clin Oncol 2003; 21: 3853-8.
57. Lambooy LH, Gidding CE, van den Heuvel LP, Hulsbergen-van den Kaa CA, Ligtenberg M, Bokkerink JP, et al. Rel-time analysis of tyrosine hydroxylase gene expression: a sensitive and seniquantitative marker for minimal residual disease detection of neuroblastoma. Clin Canc Res 2003; 9: 812-9.
58. Cheung IY, Lo Piccolo MS, Kushner BH, Kramer K, Cheung NK. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol 2003; 21: 1087-93.
59. Combaret V, Audoynaud C, Iacono I, Favrot MC, Schell M, Bergeron C, Puisieux A. Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. Cancer Res. 2002; 62: 3646-8.
60. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer. 2001; 1: 181-93.
61. Chu PW, Cheung WM, Kwong YL. Differential effects of 9-cis, 13-cis and all-trans retinoic acids on the neuronal differentiation of human neuroblastoma cells. Neuroreport 2003; 14: 1935-9.
62. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Lett. 2003; 197: 185-92.
63. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999; 341: 1165-73.
64. Tonini GP, Mazzocco K, Di Vinci A, Geido E, De Bernardi B, Giaretti W. Evidence of apoptosis in neuroblastoma at onset and relapse. An analysis of a large series of tumors. Journal of Neuro-Oncology 1997: 31: 209-15.
65. Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, et al. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res. 1995; 55: 853-61.
66. Ponthan F, Lindskog M, Karnehed N, Castro J, Kogner P. Evaluation of anti-tumour effects of oral fenretinide (4-HPR) in rats with human neuroblastoma xenografts. Oncol Rep. 2003; 10: 1587-92.
67. Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, Pizzitola MR, et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res. 2003; 9: 2032-39.
68. Raffaghello L, Pagnan G, Pastorino F, Cosimo E, Brignole C, Marimpietri D, et al. In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma. Int J Cancer. 2003;104: 559-67.
69. Ribatti D, Alessandri G, Baronio M, Raffaghello L, Cosimo E, Marimpietri D, et al. Inhibition of neuroblastoma-induced angiogenesis by fenretinide. Int J Cancer. 2001; 94:314-21.
70. Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 1984; 44: 5914-20.
71. Yu AL, Uttenreuther-Fischer MM, Huang CS, Tsui CC, Gillies SD, Reisfeld RA, et al. Phase I trial of a human-mouse chimeric antidisialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998; 16: 2169-80.
72. Kushner BH, Kramer K, Cheung NK. Phase II trial of the anti-D(D2) monoclonal antibody 3F8 and granulocye-macrophage colony stimulating factor for neuroblastoma. J Clin Oncol 2001; 19: 4189-94.
73. Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, et al. A phase I/Ib trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 1997; 80: 317-33.
74. Bestagno M, Occhino M, Corrias MV, Burrone O, Pistoia V. Recombinant antibodies in the immunotherapy of neuroblastoma: perspectives of new developments. Cancer Lett. 2003; 197: 193-8.
75. Sen G, Chakraborty M, Foon KA, Reisfeld A, Bhattacharya-Chatterje M. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody the mimics the disialoganglioside GD2. Clin Cancer Res 1997; 3: 1969-76.
76. Ollert MW, David K, Schmitt C, Hauenschild A, Brederhorst R, Erttmann R, Vogel CW. Normal human serum contains a natural IgM cytotoxic for human neuroblastoma cells. Proc Natl Acad Sci USA 1996; 93: 4498-503.
77. David K, Ollert MW, Juhl H, Vollmert C, Erttmann R, Vogel CW et al. Growth arrest of solid human neuroblastoma xenografts in nude rats by natural IgM from healthy humans. Nat Med 1996; 2: 686-9.
78. David K, Heiligtag S, Ollert MW, Teppke M, Vogel CW, Brederhorst R. Initial characterization of the apoptosis-inducing receptor for natural human anti-neuroblastoma IgM. Med Pediatr Oncol 2001; 36: 251-7.
79. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666-75.
80. Favrot M, Floret D, Michon J, Negrier S, Bouffet E, Coze C, et al. A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2in children with advanced neuroblastoma. A report on 11 cases. Cancer Treat Rev 1989; Suppl A: 129-42.
81. Pession A, Prete A, Locatelli F, Pierinelli S, Pession AL, Maccario R, et al. Immunotherapy with low-dose recombinant interleukin-2 after high dose chemotherapy and autologous stem cell transplantation in neuroblastoma. Br J Cancer 1998; 78: 528-33.
82. Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst. 1997; 89: 1586-94.
83. Airoldi I, Lualdi S, Bruno S, Raffaghello L, Occhino M, Gambini C, et al. Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40 positive neuroblastoma cells undergo apoptosis following interaction with CD40L. Brit J Cancer 2003; 88: 1527-36.
84. Rimoldi D, Romero P, Carrel S. The human melanoma antigenencoding gene, MAGE-1, is expressed by other tumor cells of neuroectodermal origin such as glioblastomas and neuroblastomas. Int J Cancer 1993; 54: 527-8.
85. Corrias MV, Scaruffi P, Occhino M, De Bernardi B, Tonini GP, Pistoia V. Expression of MAGE-1, MAGE-3, and MART-1 genes in neuroblastoma. Int J Cancer 1996; 69: 403-7.
86. Ishida H, Matsumura T, Salgaller ML, Ohmizono Y, Kadono Y, Sawada T. MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors. Int J Cancer 1996; 69: 375-80.
87. Cheung IY, Barber D, Cheung NK. Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers. Clin Cancer Res 1998; 4: 2801-5.
88. Sarkar AK, Nuchtern JG. Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes. Cancer Res 2000; 60: 1908-13.
89. Passoni L, Scardino A, Bertazzoli C, Gallo B, Cosuccia AM, Lemonnier FA, et al. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1 restricted CD8+ T-cell epitopes. Blood 2002; 99: 2100-6.
90. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant T cells. Sem Cancer Biol 2002; 12: 3-13.
91. Lampson LA, Fisher CA, Whelan JP. Striking paucity of HLA-A, B, C and b2-microglobulin on human neuroblastoma cell lines. J Immunol 1983; 130: 2471-8.
92. Corrias MV, Occhino M, Croce M, De Ambrosis A, Pistillo MP, Bocca P, et al. Lack of HLA-class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression. Tissues Antigens 2001; 57: 110-7.
93. Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001; 61: 8513-9.
94. Moretta A, Biassoni R, Bottino C., Pende D, Vitale M, Poggi A., et al. Major histocompatibility complex class I-specific receptors on human natural killer lymphocytes. Immunol Rev 1997: 155: 105-17.
95. Sivori S, Parolini S, Marcenaro L, Castriconi R, Pende D, Millo R, et al. Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines. J Neuroimmunol 2000; 107: 220-5.
96. Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of humna neuroblastoma. Neoplasia 2004 (in press)
97. Valteau-Couanet D, Leboulaire C, Maincent K, Tournier M, Hartmann O, Benard J, et al.Dendritic cells for NK/LAK activation: rationale for multicellular immnuotherapy in neuroblastoma patients. Blood 2002; 100: 2554-61.
98. Bowman L, Grossmann M, Brown M, Zhong WY, Alexander B, Leimig T, et al. IL-2 adenovector-transduced autologous tumor cells induce antitumour immune responses in patients with neuroblastoma. Blood 1998; 92: 1941-9.
99. Bowman LC, Grossmann M, Rill D, Brown M, Zhong WY, Alexander B, et al. Interleukin-2 gene modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther 1998; 9: 1303-11.
100. Rousseau RF, Haight AE, Hirschmann-Jax C, Yvon ES, Rill DR, Mei Z, Smith SC, et al. Local and systemic effects of an allogeneic tumor vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003; 101: 1718-26.
101. Corrias MV, Basso S, Meazza R, Musiani P, Santi L, Bocca P, et al. Characterization and tumorigencity of human neuroblastoma cells transfected with the IL-2 gene. Cancer Gene Ther 1998; 5: 38-44.
102. Pertl U, Luster AD, Varki NM, Homann D, Gaedicke G, Reisfeld RA, et al. IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J Immunol 2001; 66: 6944-51.
103. Hedrick JA, Zlotnik A. Lymphotactin. Clin Immunol Immunopathol 1998; 87: 218-22.
104. Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 1998; 188: 619-26.
105. Rossig C, Bollard CM, Nuchtern JG, Merchant DA, Brenner MK. Targeting of G(D)2-positive tumor cells to human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer 2001; 94: 228-36.
106. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003; 302: 415-9.
107. Crooke St. Progress in antisense technology. Annu Rev Med 2004; 55: 61-95.
108. Dean NM, Bennet CF. Antisense oligonucleotides-based therapeutics for cancer. Oncogene 2003; 22: 9087-96.
109. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-60.
110. Pagnan G, Stuart DD, Pastorino F, Raffaghello L, Montaldo PG, Allen TM, et al. Delivery of c-myb antisense oliodeoxynucleotides to human neuroblastoma via disialoganglioside GD(2)-targeted immunoliposomes: antitumour effects. J Natl Canc Inst 2000; 92: 253-61.
111. Burkhart CA, Cheng AJ, Madafiglio J, Kavallaris M, Mili M, Marshall GM, et al. Effects of MYCN antisense oligonucleotides administration on tumorigenesis in a murine model of neuroblastoma. J Natl Canc Inst 2003; 95: 1394-403.
112. Weiss W, Aldape K, Mohapatra G, Feuerstein B, Bishop J. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997; 16: 2985-95.
113. Carpentier AF, Chen L, Maltonti F, Delattre JY. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999; 59: 5429-32.
114. Folkman J, D'Amore P. Blood vessel formation: what is its molecular basis? Cell 1996; 86: 353-64.
115. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
116. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
117. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, et al. Evidence for circulating bone-marrow derived endothelial cells. Blood 1998; 92: 362-7.
118. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995; 1: 27-31.
119. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
120. Klagsbrun M, D'Amore P. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996; 7:259-70.
121. Klagsbrun M., Moses MA. Molecular angiogenesis. Chem Biol 1999; 6:217-24.
122. Ribatti D, Vacca A, Nico B, De Falco G, Montaldo PG, Ponzoni M. Angiogenesis and anti-angiogenesis in neuroblastoma. Eur J Cancer 2002; 38: 750-7.
123. Chlenski A, Liu S, Cohn S. The regulation of angiogenesis in neuroblastoma. Cancer Letters 2003; 197: 47-52.
124. Ribatti D, Alessandri G, Vacca A, Iurlaro M, Ponzoni M. Human neuroblastoma cells produce extracellular matrix-degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo. Int J Cancer 1998; 77: 449-54.
125. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161-95,
126. Ribatti D, Surico G, Vacca A, De Leonardis F, Lastilla G, Montaldo PG, et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci 2001; 68: 1161-8.
127. Falm E. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 2004; 90: 1-7.
128. Gordon MS, Margolin K, Talpaz M, Sledge Jr. GW, Holmgren E, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-50.
129. Kim E, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, et al. Proc. Natl Acad Sci USA 2002; 99: 11399-404.
130. Erdreich-Epstein A, Shimada H, Groshen S, Liu M, Metelitsa LS, Kim KS, et al. Integrins avb3 and avb5 are expressed by endothelium of high risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res 2000; 60: 712-21.
131. Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 2003; 63: 7400-9.
132. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-6.
133. Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatininb (STI571). Eur J Cancer 2002; 38 Suppl 5: S28-36.
134. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
135. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001; 344:1052-6.
136. Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst. 2004; 96: 46-55.
137. Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med. 2001; 7: 673-9
138. Ohira M, Morohashi A, Inuzuka H, Shishikura T, Kawamoto T, Kageyama H, et al. Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets. Oncogene. 2003; 22: 5525-36.
139. Alaminos M, Mora J, Cheung NK, Smith A, Qin J, Chen L, et al. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. Cancer Res. 2003; 63: 4538-46.
140. Raetz EA, Kim MK, Moos P, Carlson M, Bruggers C, Hooper DK, et al. Identification of genes that are regulated transcriptionally by Myc in childhood tumors. Cancer 2003; 98: 841-53.
141. Hiyama E, Hiyama K, Yamaoka H, Sueda T, Reynolds CP, Yokoyama T. Expression profiling of favorable and unfavorable neuroblastomas. Pediatr Surg Int 2004; 20: 33-8.
142. Fan J, Tam P, Woude GV, Ren Y. Normalization and analysis of cDNA microarrays using within-array replications applied to neuroblastoma cell response to a cytokine. Proc Natl Acad Sci USA. 2004; 101: 1135-40.
143. Yuza Y, Agawa M, Matsuzaki M, Yamada H, Urashima M. Gene and protein expression profiling during differentiation of neuroblastoma cells triggered by 13-cis retinoic acid. J Pediatr Hematol Oncol. 2003; 25: 715-20
144. Takita J, Ishii M, Tsutsumi S, Tanaka Y, Kato K, Toyoda Y et al. Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma. Genes Chromosomes Cancer. 2004 Jun;40(2):120-32
145. Kallionemi O. Profile of a tumor. Nature 2004; 428: 379-82.